|Daily Range||$145.47 - $147.72|
|52-Week Range||$124.36 - $147.72|
|Dividend (Yield)||$0.00 (1.4%)|
|Average Daily Volume||48,095|
|Current FY EPS||$7.61|
News & Commentary
Ophthotech's Fovista may tip the scale in favor of either Novartis' Lucentis or Regeneron's Eylea.
As if people didn’t hate Monsanto enough, they’re now going against the EPA and further harming this crucial insect.
Falling markets may be creating an opportunity to pick up these three biotechnology companies at discount prices.
The over-the-counter drug market could grow to reach $70 billion in sales by 2015, but according to Brand Keys, this OTC pain reliever is lagging far behind its peers in terms of customer loyalty.
Though not earth-shattering, the largest study to date represents a continued move away from chemical use.
Regeneron recently got some good news. Check out the video below for more information.
Intel, Caterpillar, and Merck were the Dow's best performers in the first half of 2014. Why did these three stocks race ahead, and where are they going next?
OncoMed shares dive after it voluntarily halts two early-stage programs. Find out what investors should be closely monitoring going forward.
Orexigen, Portola, and Regeneron could all make waves across the health care sector this Wednesday morning.
Why this acquisition made sense for both sides.